非小细胞肺癌脑转移的靶向和免疫治疗

脑转移是非小细胞肺癌（non-small cell lung cancer, NSCLC）常见并发症，发生率为30%-50%，大大影响了患者的生存质量。NSCLC一旦发生脑转移预后极差，未经治疗者的中位生存期仅为1个月-2个月。基于肺癌驱动基因的靶向治疗为肺癌脑转移提供了新的方法。目前免疫治疗已成为肿瘤治疗的新方向，它能通过刺激机体免疫系统提高抗肿瘤免疫效应。临床上靶向治疗和免疫治疗的结合运用可使患者获益。

Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer with Brain Metastasis

Brain metastasis, a common complication of non-small cell lung cancer (NSCLC) with an incidence rate of 30%-50%, signiifcantly affects the patients’ quality of life. hTe prognosis of patients of NSCLC with brain metastasis is ex-tremely poor, the average median survival is only 1 m-2 m without treatment. hTe targeted therapy based on lung cancer driven gene is a new treatment. Besides, the immunotherapy which can enhance the effect of anti-cancer by simulating the immune system is a new approach. The combination of targeted therapy and immunotherapy can greatly benefit patients in clinical work.